complement c3 protein Search Results


94
Shanghai Korain Biotech Co Ltd human complement component c5 elisa kit
Human Complement Component C5 Elisa Kit, supplied by Shanghai Korain Biotech Co Ltd, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/complement+c3+protein/pm41913674-58-7-16?v=Shanghai+Korain+Biotech+Co+Ltd
Average 94 stars, based on 1 article reviews
human complement component c5 elisa kit - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier

93
R&D Systems recombinant mouse c3a
Figure 2. In vitro function of islets pre-cultured with exogenous complement component <t>C3a.</t> Insulin release at 2 mmol/L and 20 mmol/L glucose of 1020 replicates of three mouse islets per Eppendorf tube: (A) pre-cultured alone, with 10 nmol/L C3a alone or with 100 nmol/L C3a alone, for 48 h followed by subsequent GSIS assays in the absence of exogenous C3a; (B) pre-cultured alone, with 5 nmol/L ANXA1 alone or with 10 nmol/L C3a alone for 48 h followed by subsequent GSIS assays in the absence of exogenous C3a or ANXA1; (C) pre-cul- tured alone, with 5 nmol/L ANXA1 alone or with a dual combination of 5 nmol/L ANXA1 and 10 nmol/L C3a for 48 h followed by subse- quent GSIS assays in the absence of exogenous C3a and/or ANXA1, P < 0.05 versus islets pre-cultured alone at the same glucose concentration. (D) Protection from cytokine-induced apoptosis following a 48 h pre-culture with 5 nmol/L ANXA1-alone, 10 nmol/L C3a alone or a dual combination of 5 nmol/L ANXA1 and 10 nmol/L C3a, and the subsequent presence of specified MSC biotherapeutics during the final 20 h cytokine incubation. Eight to 12 replicates of five islets per well in each culture group assayed, *P < 0.05 versus islets pre-cul- tured alone in the presence of cytokines for the final 20 h of the 3-day culture period. The P values (AD) were calculated using two-way ANOVA Bonferroni’s post hoc test.
Recombinant Mouse C3a, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/complement+c3+protein/pm30377040-37-35-45?v=R%26D+Systems
Average 93 stars, based on 1 article reviews
recombinant mouse c3a - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier

93
R&D Systems mpt64 c3a
Figure 2: Te concentrations of complement pyrolysis products were found higher in pleural efusion than in plasma from TPE patients. (a) Complement pyrolysis products, including <t>C3a,</t> C3b, C3d, C5a, and opsonin receptors (CR1 and CR3) were detected in human tuberculosis pleural biopsy samples by immunohistochemistry. (Original magnifcation, ×200) (n 4). (b) Higher levels of complement pyrolysis products were found in pleural efusion than in plasma in TPE patients (n 20). Te concentrations of complement pyrolysis products in pleural fuid and plasma from TPE patients were measured by ELISA (n 20).
Mpt64 C3a, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/complement+c3+protein/10__1155_slash_2024_slash_5544085-90-21-26?v=R%26D+Systems
Average 93 stars, based on 1 article reviews
mpt64 c3a - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier

90
Novus Biologicals recombinant mouse c3 p3343
Figure 2: Te concentrations of complement pyrolysis products were found higher in pleural efusion than in plasma from TPE patients. (a) Complement pyrolysis products, including <t>C3a,</t> C3b, C3d, C5a, and opsonin receptors (CR1 and CR3) were detected in human tuberculosis pleural biopsy samples by immunohistochemistry. (Original magnifcation, ×200) (n 4). (b) Higher levels of complement pyrolysis products were found in pleural efusion than in plasma in TPE patients (n 20). Te concentrations of complement pyrolysis products in pleural fuid and plasma from TPE patients were measured by ELISA (n 20).
Recombinant Mouse C3 P3343, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/complement+c3+protein/pmc07354942-332-11-17?v=Novus+Biologicals
Average 90 stars, based on 1 article reviews
recombinant mouse c3 p3343 - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

93
R&D Systems recombinant mouse complement component c3a
Levels of (A) haemoglobin (Hb) in blood and (B) macrophage chemotactic protein 1 (MCP-1), (C) keratinocyte chemoattractant (KC) and (D) <t>complement</t> component <t>C3a</t> in plasma of animals 4 h after infliction of polytrauma and hemorrhagic shock (PTHS; n = 7 for Hb, n = 8 for MCP-1, KC and C3a) and native control animals (CTRL; n = 8 for Hb, n = 4 for MCP-1, n = 5 for C3a and KC). Results (B, C, D) are presented as amount of protein per total protein in plasma to unmask diluting effects from volume resuscitation. For statistical comparison of experimental means, unpaired t-tests (A, C, D) and Mann-Whitney rank sum test (B) were performed. *: p<0.05.
Recombinant Mouse Complement Component C3a, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/complement+c3+protein/pmc05662170-34-0-5?v=R%26D+Systems
Average 93 stars, based on 1 article reviews
recombinant mouse complement component c3a - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier

94
R&D Systems c5a
FIGURE 5. C3a-induced IL-6 release in human gingival epithelial cells. (A) Human immortalized gingival keratinocytes (HIGKs) were stimulated, or not, with heat-killed P. gingivalis (MOI of 10:1), C3a, or <t>C5a</t> and combinations thereof (at the indicated concentrations). Culture media were collected after a 24-h incubation and assayed for IL-6 by ELISA. (B) HIGKs were stimulated for 24 h with heat-killed P. gingivalis (MOI of 10:1) or Pam3Cys lipopeptide (1 mg/ml) and C3aR expression was measured by FACS. Representative histogram (left) and bar graphs for mean fluorescence intensity (MFI) of C3aR expression (right). (C) HIGKs were stimulated, or not, with C3a (500 ng/ml), Pam3Cys (1 mg/ml), or both, and IL-6 was measured in collected culture supernatants after a 24-h incubation. (D) HIGKs were stimulated for 24 h, or not, with P. gingivalis (MOI of 10:1) alone or with C3a (500 ng/ml), in the presence or absence of 10 mg/ml anti-TLR2 neutralizing Ab or isotype control (IC), which were added 2 h prior to stimulation. IL-6 release was assayed by ELISA. (E) HIGKs were pretreated with PD98059 (10 mM; MEK/ERK inhibitor), SP600125 (50mM; JNK inhibitor), SB202190 (20mM; p38 MAPK inhibitor), or SN50 (50mM, NF-kB inhibi- tor). After 1 h, Pam3Cys (1 mg/ml) was added in the cultures and C3aR expression (MFI) was determined by FACS after a 24-h incubation. (F) HIGKs were stimulated with Pam3Cys (1 mg/ml) for the indicated time lengths. Total protein was extracted and immunoblot analysis was performed with specific Abs against phosphorylated and total ERK1/2, JNK, and p38 MAPK as well as against GAPDH (loading control). (G) HIGKs were pretreated with Pam3Cys (1 mg/ml) for 4 h and then exposed to PD98059 (10 mM; MEK/ERK inhibitor), SP600125 (50mM; JNK inhibitor), SB202190 (20mM; p38 MAPK inhibitor), or SN50 (50mM, NF-kB inhibitor). After 1 h, C3a (500 ng/ml) was added in the cultures. Culture media were collected after 24 h and assayed for IL-6 by ELISA. Data are means ± SD (n 5 6 cultures per group). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 (A, D, E, and G, one-way ANOVA and a Tukey’s test; B and C, Dunnett’s multiple comparison tests).
C5a, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/complement+c3+protein/pm36028293-76-51-58?v=R%26D+Systems
Average 94 stars, based on 1 article reviews
c5a - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier

90
Novus Biologicals human complement c3 protein
FIGURE 5. C3a-induced IL-6 release in human gingival epithelial cells. (A) Human immortalized gingival keratinocytes (HIGKs) were stimulated, or not, with heat-killed P. gingivalis (MOI of 10:1), C3a, or <t>C5a</t> and combinations thereof (at the indicated concentrations). Culture media were collected after a 24-h incubation and assayed for IL-6 by ELISA. (B) HIGKs were stimulated for 24 h with heat-killed P. gingivalis (MOI of 10:1) or Pam3Cys lipopeptide (1 mg/ml) and C3aR expression was measured by FACS. Representative histogram (left) and bar graphs for mean fluorescence intensity (MFI) of C3aR expression (right). (C) HIGKs were stimulated, or not, with C3a (500 ng/ml), Pam3Cys (1 mg/ml), or both, and IL-6 was measured in collected culture supernatants after a 24-h incubation. (D) HIGKs were stimulated for 24 h, or not, with P. gingivalis (MOI of 10:1) alone or with C3a (500 ng/ml), in the presence or absence of 10 mg/ml anti-TLR2 neutralizing Ab or isotype control (IC), which were added 2 h prior to stimulation. IL-6 release was assayed by ELISA. (E) HIGKs were pretreated with PD98059 (10 mM; MEK/ERK inhibitor), SP600125 (50mM; JNK inhibitor), SB202190 (20mM; p38 MAPK inhibitor), or SN50 (50mM, NF-kB inhibi- tor). After 1 h, Pam3Cys (1 mg/ml) was added in the cultures and C3aR expression (MFI) was determined by FACS after a 24-h incubation. (F) HIGKs were stimulated with Pam3Cys (1 mg/ml) for the indicated time lengths. Total protein was extracted and immunoblot analysis was performed with specific Abs against phosphorylated and total ERK1/2, JNK, and p38 MAPK as well as against GAPDH (loading control). (G) HIGKs were pretreated with Pam3Cys (1 mg/ml) for 4 h and then exposed to PD98059 (10 mM; MEK/ERK inhibitor), SP600125 (50mM; JNK inhibitor), SB202190 (20mM; p38 MAPK inhibitor), or SN50 (50mM, NF-kB inhibitor). After 1 h, C3a (500 ng/ml) was added in the cultures. Culture media were collected after 24 h and assayed for IL-6 by ELISA. Data are means ± SD (n 5 6 cultures per group). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 (A, D, E, and G, one-way ANOVA and a Tukey’s test; B and C, Dunnett’s multiple comparison tests).
Human Complement C3 Protein, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/complement+c3+protein/pm26740625-46-0-8?v=Novus+Biologicals
Average 90 stars, based on 1 article reviews
human complement c3 protein - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

93
R&D Systems mouse c3d
FIGURE 5. C3a-induced IL-6 release in human gingival epithelial cells. (A) Human immortalized gingival keratinocytes (HIGKs) were stimulated, or not, with heat-killed P. gingivalis (MOI of 10:1), C3a, or <t>C5a</t> and combinations thereof (at the indicated concentrations). Culture media were collected after a 24-h incubation and assayed for IL-6 by ELISA. (B) HIGKs were stimulated for 24 h with heat-killed P. gingivalis (MOI of 10:1) or Pam3Cys lipopeptide (1 mg/ml) and C3aR expression was measured by FACS. Representative histogram (left) and bar graphs for mean fluorescence intensity (MFI) of C3aR expression (right). (C) HIGKs were stimulated, or not, with C3a (500 ng/ml), Pam3Cys (1 mg/ml), or both, and IL-6 was measured in collected culture supernatants after a 24-h incubation. (D) HIGKs were stimulated for 24 h, or not, with P. gingivalis (MOI of 10:1) alone or with C3a (500 ng/ml), in the presence or absence of 10 mg/ml anti-TLR2 neutralizing Ab or isotype control (IC), which were added 2 h prior to stimulation. IL-6 release was assayed by ELISA. (E) HIGKs were pretreated with PD98059 (10 mM; MEK/ERK inhibitor), SP600125 (50mM; JNK inhibitor), SB202190 (20mM; p38 MAPK inhibitor), or SN50 (50mM, NF-kB inhibi- tor). After 1 h, Pam3Cys (1 mg/ml) was added in the cultures and C3aR expression (MFI) was determined by FACS after a 24-h incubation. (F) HIGKs were stimulated with Pam3Cys (1 mg/ml) for the indicated time lengths. Total protein was extracted and immunoblot analysis was performed with specific Abs against phosphorylated and total ERK1/2, JNK, and p38 MAPK as well as against GAPDH (loading control). (G) HIGKs were pretreated with Pam3Cys (1 mg/ml) for 4 h and then exposed to PD98059 (10 mM; MEK/ERK inhibitor), SP600125 (50mM; JNK inhibitor), SB202190 (20mM; p38 MAPK inhibitor), or SN50 (50mM, NF-kB inhibitor). After 1 h, C3a (500 ng/ml) was added in the cultures. Culture media were collected after 24 h and assayed for IL-6 by ELISA. Data are means ± SD (n 5 6 cultures per group). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 (A, D, E, and G, one-way ANOVA and a Tukey’s test; B and C, Dunnett’s multiple comparison tests).
Mouse C3d, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/complement+c3+protein/pm41082629-29-29-34?v=R%26D+Systems
Average 93 stars, based on 1 article reviews
mouse c3d - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier

94
R&D Systems mouse complement component c3d
The strong correlation between <t>complement</t> activation and CRC. ( A-D ) The associations between the mRNA levels of C3 (A), C5 (B), C5AR1 (C), and C5AR2 (D) and the overall survival of CRC patients (n=364). ( E, F ) The effect of C3 , C5 , C5ar1 or C5ar2 deficiency on AOM/DSS-induced colorectal tumorigenesis compared to WT control. Images of the colorectum, where CRC often developed at distal (rectum) sites (E), and quantitative analysis of tumor number and mass (F). The experiment was duplicated. Scale bar in (E), 1 cm. ( G ) Pathological analysis of control or tumor tissues, including H&E, Ki-67 and <t>C3d</t> staining. Scale bar, 100 µm for H&E and 50 µm for IHC. ( H ) C5a concentration in colon tissue homogenates (CTHs) measured by ELISA. n≥ 7 in each group of WT, C3 -KO, C5 -KO, C5ar1 -KO, or C5ar2 -KO mice. Data are represented as mean ± SEM; ns, not significant; * P <0.05; and *** P <0.001. NC, negative control.
Mouse Complement Component C3d, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/complement+c3+protein/pmc07392014-43-13-18?v=R%26D+Systems
Average 94 stars, based on 1 article reviews
mouse complement component c3d - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier

92
Boster Bio antibodies against complement 3 c3
The strong correlation between <t>complement</t> activation and CRC. ( A-D ) The associations between the mRNA levels of C3 (A), C5 (B), C5AR1 (C), and C5AR2 (D) and the overall survival of CRC patients (n=364). ( E, F ) The effect of C3 , C5 , C5ar1 or C5ar2 deficiency on AOM/DSS-induced colorectal tumorigenesis compared to WT control. Images of the colorectum, where CRC often developed at distal (rectum) sites (E), and quantitative analysis of tumor number and mass (F). The experiment was duplicated. Scale bar in (E), 1 cm. ( G ) Pathological analysis of control or tumor tissues, including H&E, Ki-67 and <t>C3d</t> staining. Scale bar, 100 µm for H&E and 50 µm for IHC. ( H ) C5a concentration in colon tissue homogenates (CTHs) measured by ELISA. n≥ 7 in each group of WT, C3 -KO, C5 -KO, C5ar1 -KO, or C5ar2 -KO mice. Data are represented as mean ± SEM; ns, not significant; * P <0.05; and *** P <0.001. NC, negative control.
Antibodies Against Complement 3 C3, supplied by Boster Bio, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/complement+c3+protein/pmc09896989-82-16-24?v=Boster+Bio
Average 92 stars, based on 1 article reviews
antibodies against complement 3 c3 - by Bioz Stars, 2026-07
92/100 stars
  Buy from Supplier

93
Boster Bio mac 1
The strong correlation between <t>complement</t> activation and CRC. ( A-D ) The associations between the mRNA levels of C3 (A), C5 (B), C5AR1 (C), and C5AR2 (D) and the overall survival of CRC patients (n=364). ( E, F ) The effect of C3 , C5 , C5ar1 or C5ar2 deficiency on AOM/DSS-induced colorectal tumorigenesis compared to WT control. Images of the colorectum, where CRC often developed at distal (rectum) sites (E), and quantitative analysis of tumor number and mass (F). The experiment was duplicated. Scale bar in (E), 1 cm. ( G ) Pathological analysis of control or tumor tissues, including H&E, Ki-67 and <t>C3d</t> staining. Scale bar, 100 µm for H&E and 50 µm for IHC. ( H ) C5a concentration in colon tissue homogenates (CTHs) measured by ELISA. n≥ 7 in each group of WT, C3 -KO, C5 -KO, C5ar1 -KO, or C5ar2 -KO mice. Data are represented as mean ± SEM; ns, not significant; * P <0.05; and *** P <0.001. NC, negative control.
Mac 1, supplied by Boster Bio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/complement+c3+protein/bio_rxiv__2022__03__29__486223-229-2-30?v=Boster+Bio
Average 93 stars, based on 1 article reviews
mac 1 - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier

93
Boster Bio rabbit anti c3b monoclonal antibody
Inhibition of <t>C3b</t> and C4b deposition by r Em CRT and its functional binding regions measured by ELISA. ( A ) Pre-incubation of 100 μL C1qD (1:50) as source of natural MBL with different amounts of r Em CRT, r Em CRT-S, or r Em CRT-NP (0, 2, 4 μM) before adding into mannan-coated plates (50 μg/mL). After being washed, C1qD (1:150) was added as source of complement components to initiate lectin pathway of complement activation. Deposition of C3b ( a ) and C4b ( b ) was detected with anti-C3 or C4 <t>monoclonal</t> antibodies. ( B ) The similar ELISA procedure was performed using NHS as source of physiological MBL instead of C1qD serum to detect the generation of C3b (a) and C4b (b). Data are expressed as mean of OD 450 ± SDs of three independent experiments (* p < 0.005, ** p < 0.001, *** p < 0.0005, ns, no significant difference compared to plates without added r Em CRT).
Rabbit Anti C3b Monoclonal Antibody, supplied by Boster Bio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/complement+c3+protein/pmc12030537-64-65-70?v=Boster+Bio
Average 93 stars, based on 1 article reviews
rabbit anti c3b monoclonal antibody - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier

Image Search Results


Figure 2. In vitro function of islets pre-cultured with exogenous complement component C3a. Insulin release at 2 mmol/L and 20 mmol/L glucose of 1020 replicates of three mouse islets per Eppendorf tube: (A) pre-cultured alone, with 10 nmol/L C3a alone or with 100 nmol/L C3a alone, for 48 h followed by subsequent GSIS assays in the absence of exogenous C3a; (B) pre-cultured alone, with 5 nmol/L ANXA1 alone or with 10 nmol/L C3a alone for 48 h followed by subsequent GSIS assays in the absence of exogenous C3a or ANXA1; (C) pre-cul- tured alone, with 5 nmol/L ANXA1 alone or with a dual combination of 5 nmol/L ANXA1 and 10 nmol/L C3a for 48 h followed by subse- quent GSIS assays in the absence of exogenous C3a and/or ANXA1, P < 0.05 versus islets pre-cultured alone at the same glucose concentration. (D) Protection from cytokine-induced apoptosis following a 48 h pre-culture with 5 nmol/L ANXA1-alone, 10 nmol/L C3a alone or a dual combination of 5 nmol/L ANXA1 and 10 nmol/L C3a, and the subsequent presence of specified MSC biotherapeutics during the final 20 h cytokine incubation. Eight to 12 replicates of five islets per well in each culture group assayed, *P < 0.05 versus islets pre-cul- tured alone in the presence of cytokines for the final 20 h of the 3-day culture period. The P values (AD) were calculated using two-way ANOVA Bonferroni’s post hoc test.

Journal: Cytotherapy

Article Title: Mesenchymal stromal cell secretory factors induce sustained improvements in islet function pre- and post-transplantation.

doi: 10.1016/j.jcyt.2018.07.007

Figure Lengend Snippet: Figure 2. In vitro function of islets pre-cultured with exogenous complement component C3a. Insulin release at 2 mmol/L and 20 mmol/L glucose of 1020 replicates of three mouse islets per Eppendorf tube: (A) pre-cultured alone, with 10 nmol/L C3a alone or with 100 nmol/L C3a alone, for 48 h followed by subsequent GSIS assays in the absence of exogenous C3a; (B) pre-cultured alone, with 5 nmol/L ANXA1 alone or with 10 nmol/L C3a alone for 48 h followed by subsequent GSIS assays in the absence of exogenous C3a or ANXA1; (C) pre-cul- tured alone, with 5 nmol/L ANXA1 alone or with a dual combination of 5 nmol/L ANXA1 and 10 nmol/L C3a for 48 h followed by subse- quent GSIS assays in the absence of exogenous C3a and/or ANXA1, P < 0.05 versus islets pre-cultured alone at the same glucose concentration. (D) Protection from cytokine-induced apoptosis following a 48 h pre-culture with 5 nmol/L ANXA1-alone, 10 nmol/L C3a alone or a dual combination of 5 nmol/L ANXA1 and 10 nmol/L C3a, and the subsequent presence of specified MSC biotherapeutics during the final 20 h cytokine incubation. Eight to 12 replicates of five islets per well in each culture group assayed, *P < 0.05 versus islets pre-cul- tured alone in the presence of cytokines for the final 20 h of the 3-day culture period. The P values (AD) were calculated using two-way ANOVA Bonferroni’s post hoc test.

Article Snippet: Islets were handpicked into groups of 100 for pre-culture in RPMI supplemented with 10% fetal bovine serum (FBS) and 100 U/mL penicillin plus 0.1 mg/mL streptomycin alone, with recombinant human ANXA1 alone, recombinant mouse SDF-1-alone, recombinant mouse C3a alone or with combinations of these factors (R&D Systems, Abingdon, United Kingdom).

Techniques: In Vitro, Cell Culture, Concentration Assay, Incubation

Figure 3. Pre-culturing islets with a cocktail of MSC secretory factors ensures sustained improvements to islet insulin secretory function and protection from cytokine-induced apoptosis. (A, B) Insulin release at 2 and 20 mmol/L glucose of 30 replicates of three mouse islets per Eppendorf tube, pre-cultured alone, with 5 nmol/L ANXA1 alone, with 5 nmol/L ANXA1 and 10 nmol/L SDF-1, with 5 nmol/L ANXA1 and 10 nmol/L C3a, or with a cocktail of 5 nmol/L ANXA1, 10 nmol/L SDF-1 and 10 nmol/L C3a, for 48 h, before removal of the MSC- derived biotherapeutics for 1 day (A) or 3 days (B), *P < 0.05 and **P < 0.01 versus islets cultured alone at the same glucose concentration. (C, D) Protection of islets from cytokine-induced apoptosis after pre-culture with MSC-derived biotherapeutics alone, in dual combination or a cocktail of all three factors (as of legend) for 48 h, before removal of the MSC-derived biotherapeutics for 1 day (C) or 3 days (D), 8 to 12 replicates of five islets per well were assayed, *P < 0.05 and **P < 0.01 versus islets cultured alone with cytokines, +P < 0.05 vs. islets cul- tured alone without cytokines. The P values (AD) were calculated using two-way ANOVA with Bonferroni post hoc test.

Journal: Cytotherapy

Article Title: Mesenchymal stromal cell secretory factors induce sustained improvements in islet function pre- and post-transplantation.

doi: 10.1016/j.jcyt.2018.07.007

Figure Lengend Snippet: Figure 3. Pre-culturing islets with a cocktail of MSC secretory factors ensures sustained improvements to islet insulin secretory function and protection from cytokine-induced apoptosis. (A, B) Insulin release at 2 and 20 mmol/L glucose of 30 replicates of three mouse islets per Eppendorf tube, pre-cultured alone, with 5 nmol/L ANXA1 alone, with 5 nmol/L ANXA1 and 10 nmol/L SDF-1, with 5 nmol/L ANXA1 and 10 nmol/L C3a, or with a cocktail of 5 nmol/L ANXA1, 10 nmol/L SDF-1 and 10 nmol/L C3a, for 48 h, before removal of the MSC- derived biotherapeutics for 1 day (A) or 3 days (B), *P < 0.05 and **P < 0.01 versus islets cultured alone at the same glucose concentration. (C, D) Protection of islets from cytokine-induced apoptosis after pre-culture with MSC-derived biotherapeutics alone, in dual combination or a cocktail of all three factors (as of legend) for 48 h, before removal of the MSC-derived biotherapeutics for 1 day (C) or 3 days (D), 8 to 12 replicates of five islets per well were assayed, *P < 0.05 and **P < 0.01 versus islets cultured alone with cytokines, +P < 0.05 vs. islets cul- tured alone without cytokines. The P values (AD) were calculated using two-way ANOVA with Bonferroni post hoc test.

Article Snippet: Islets were handpicked into groups of 100 for pre-culture in RPMI supplemented with 10% fetal bovine serum (FBS) and 100 U/mL penicillin plus 0.1 mg/mL streptomycin alone, with recombinant human ANXA1 alone, recombinant mouse SDF-1-alone, recombinant mouse C3a alone or with combinations of these factors (R&D Systems, Abingdon, United Kingdom).

Techniques: Cell Culture, Derivative Assay, Concentration Assay

Figure 4. In vivo function of islets pre-cultured alone, with ANXA1 alone or with a cocktail of MSC secretory factors. (A) Average blood glucose concentrations of STZ diabetic mice trans- planted with 150 islets pre-cultured for 48 h alone, with ANXA1 alone or with a cocktail of ANXA1/SDF-1/C3a, *P < 0.05 versus mice transplanted with islets pre-cultured alone (repeated-meas- urements ANOVA with Bonferroni post hoc test, n = 79). (B) Area under the curve (AUC) of STZ diabetic mice transplanted with 150 islets pre-cultured for 48 h alone, with ANXA1 alone or with a cocktail of ANXA1/SDF-1/C3a, *P < 0.05 versus mice transplanted with islets pre-cultured alone (one-way ANOVA with Dunn’s post hoc test, n = 79).

Journal: Cytotherapy

Article Title: Mesenchymal stromal cell secretory factors induce sustained improvements in islet function pre- and post-transplantation.

doi: 10.1016/j.jcyt.2018.07.007

Figure Lengend Snippet: Figure 4. In vivo function of islets pre-cultured alone, with ANXA1 alone or with a cocktail of MSC secretory factors. (A) Average blood glucose concentrations of STZ diabetic mice trans- planted with 150 islets pre-cultured for 48 h alone, with ANXA1 alone or with a cocktail of ANXA1/SDF-1/C3a, *P < 0.05 versus mice transplanted with islets pre-cultured alone (repeated-meas- urements ANOVA with Bonferroni post hoc test, n = 79). (B) Area under the curve (AUC) of STZ diabetic mice transplanted with 150 islets pre-cultured for 48 h alone, with ANXA1 alone or with a cocktail of ANXA1/SDF-1/C3a, *P < 0.05 versus mice transplanted with islets pre-cultured alone (one-way ANOVA with Dunn’s post hoc test, n = 79).

Article Snippet: Islets were handpicked into groups of 100 for pre-culture in RPMI supplemented with 10% fetal bovine serum (FBS) and 100 U/mL penicillin plus 0.1 mg/mL streptomycin alone, with recombinant human ANXA1 alone, recombinant mouse SDF-1-alone, recombinant mouse C3a alone or with combinations of these factors (R&D Systems, Abingdon, United Kingdom).

Techniques: In Vivo, Cell Culture

Figure 2: Te concentrations of complement pyrolysis products were found higher in pleural efusion than in plasma from TPE patients. (a) Complement pyrolysis products, including C3a, C3b, C3d, C5a, and opsonin receptors (CR1 and CR3) were detected in human tuberculosis pleural biopsy samples by immunohistochemistry. (Original magnifcation, ×200) (n 4). (b) Higher levels of complement pyrolysis products were found in pleural efusion than in plasma in TPE patients (n 20). Te concentrations of complement pyrolysis products in pleural fuid and plasma from TPE patients were measured by ELISA (n 20).

Journal: International Journal of Clinical Practice

Article Title: Pleural Mesothelial Cells-Induced Monocytes to the Pleural Cavity through the Effect of C3 Lytic Products in Tuberculous Pleural Effusion

doi: 10.1155/2024/5544085

Figure Lengend Snippet: Figure 2: Te concentrations of complement pyrolysis products were found higher in pleural efusion than in plasma from TPE patients. (a) Complement pyrolysis products, including C3a, C3b, C3d, C5a, and opsonin receptors (CR1 and CR3) were detected in human tuberculosis pleural biopsy samples by immunohistochemistry. (Original magnifcation, ×200) (n 4). (b) Higher levels of complement pyrolysis products were found in pleural efusion than in plasma in TPE patients (n 20). Te concentrations of complement pyrolysis products in pleural fuid and plasma from TPE patients were measured by ELISA (n 20).

Article Snippet: Monocytes isolated from TPE were incubated in the presence of medium alone or with MPT64 (20 μg/ml, Goodhere Biotechnology, Hangzhou, China), MPT64 +C3a (100 nM, 3677-C3-025, R&D Systems), MPT64+C3aRA (100 nM, SB290157, Calbiochem), or MPT64 +C3a +C3aRA.

Techniques: Clinical Proteomics, Immunohistochemistry, Enzyme-linked Immunosorbent Assay

Figure 3: Monocyte migration was inhibited by antibodies that blocked CXCL12. (a) CXCL12 and CXCR4 staining by immunohisto- chemistry in human pleural biopsy (original magnifcation, ×200) (n 4). (b) Te concentration of CXCL12 in pleural fuid and plasma from TPE patients was measured by ELISA (n 20). (c) CXCL12 produced by PMCs was measured by PCR and ELISA after Mpt64 and anaphylatoxin activation. PMCs were incubated for 24 hours in control media or in media with Mpt64 (20 μg/ml) and with or without human C3a (100 nM) or C3aRA (100 nM) (n 4). (d) Coexpression of CXCL12-CXCR4 in PMCs and monocytes from TPE was detected by immunofuorescence (original magnifcation, ×400) (n 4). (e) Monocytes were seeded into the top chamber of a transwell system, and the supernatant from PMCs cultured with anti-CXCL12 antibody or PBS were placed in the bottom chamber. Te migratory index was calculated by dividing the number of monocytes that migrated in response to the supernatants from cultured PMCs by the number of monocytes that migrated in response to the control. ∗vs the MO-PBS group, ∗∗P < 0.01. #vs the MO-PMC group, ##P < 0.01 (n 4).

Journal: International Journal of Clinical Practice

Article Title: Pleural Mesothelial Cells-Induced Monocytes to the Pleural Cavity through the Effect of C3 Lytic Products in Tuberculous Pleural Effusion

doi: 10.1155/2024/5544085

Figure Lengend Snippet: Figure 3: Monocyte migration was inhibited by antibodies that blocked CXCL12. (a) CXCL12 and CXCR4 staining by immunohisto- chemistry in human pleural biopsy (original magnifcation, ×200) (n 4). (b) Te concentration of CXCL12 in pleural fuid and plasma from TPE patients was measured by ELISA (n 20). (c) CXCL12 produced by PMCs was measured by PCR and ELISA after Mpt64 and anaphylatoxin activation. PMCs were incubated for 24 hours in control media or in media with Mpt64 (20 μg/ml) and with or without human C3a (100 nM) or C3aRA (100 nM) (n 4). (d) Coexpression of CXCL12-CXCR4 in PMCs and monocytes from TPE was detected by immunofuorescence (original magnifcation, ×400) (n 4). (e) Monocytes were seeded into the top chamber of a transwell system, and the supernatant from PMCs cultured with anti-CXCL12 antibody or PBS were placed in the bottom chamber. Te migratory index was calculated by dividing the number of monocytes that migrated in response to the supernatants from cultured PMCs by the number of monocytes that migrated in response to the control. ∗vs the MO-PBS group, ∗∗P < 0.01. #vs the MO-PMC group, ##P < 0.01 (n 4).

Article Snippet: Monocytes isolated from TPE were incubated in the presence of medium alone or with MPT64 (20 μg/ml, Goodhere Biotechnology, Hangzhou, China), MPT64 +C3a (100 nM, 3677-C3-025, R&D Systems), MPT64+C3aRA (100 nM, SB290157, Calbiochem), or MPT64 +C3a +C3aRA.

Techniques: Migration, Staining, Immunohistochemistry, Concentration Assay, Clinical Proteomics, Enzyme-linked Immunosorbent Assay, Produced, Activation Assay, Incubation, Control, Cell Culture

Levels of (A) haemoglobin (Hb) in blood and (B) macrophage chemotactic protein 1 (MCP-1), (C) keratinocyte chemoattractant (KC) and (D) complement component C3a in plasma of animals 4 h after infliction of polytrauma and hemorrhagic shock (PTHS; n = 7 for Hb, n = 8 for MCP-1, KC and C3a) and native control animals (CTRL; n = 8 for Hb, n = 4 for MCP-1, n = 5 for C3a and KC). Results (B, C, D) are presented as amount of protein per total protein in plasma to unmask diluting effects from volume resuscitation. For statistical comparison of experimental means, unpaired t-tests (A, C, D) and Mann-Whitney rank sum test (B) were performed. *: p<0.05.

Journal: PLoS ONE

Article Title: Early structural changes of the heart after experimental polytrauma and hemorrhagic shock

doi: 10.1371/journal.pone.0187327

Figure Lengend Snippet: Levels of (A) haemoglobin (Hb) in blood and (B) macrophage chemotactic protein 1 (MCP-1), (C) keratinocyte chemoattractant (KC) and (D) complement component C3a in plasma of animals 4 h after infliction of polytrauma and hemorrhagic shock (PTHS; n = 7 for Hb, n = 8 for MCP-1, KC and C3a) and native control animals (CTRL; n = 8 for Hb, n = 4 for MCP-1, n = 5 for C3a and KC). Results (B, C, D) are presented as amount of protein per total protein in plasma to unmask diluting effects from volume resuscitation. For statistical comparison of experimental means, unpaired t-tests (A, C, D) and Mann-Whitney rank sum test (B) were performed. *: p<0.05.

Article Snippet: Recombinant mouse complement component C3a (R&D Systems, Germany) served for calculation of a standard curve.

Techniques: Clinical Proteomics, Control, Comparison, MANN-WHITNEY

FIGURE 5. C3a-induced IL-6 release in human gingival epithelial cells. (A) Human immortalized gingival keratinocytes (HIGKs) were stimulated, or not, with heat-killed P. gingivalis (MOI of 10:1), C3a, or C5a and combinations thereof (at the indicated concentrations). Culture media were collected after a 24-h incubation and assayed for IL-6 by ELISA. (B) HIGKs were stimulated for 24 h with heat-killed P. gingivalis (MOI of 10:1) or Pam3Cys lipopeptide (1 mg/ml) and C3aR expression was measured by FACS. Representative histogram (left) and bar graphs for mean fluorescence intensity (MFI) of C3aR expression (right). (C) HIGKs were stimulated, or not, with C3a (500 ng/ml), Pam3Cys (1 mg/ml), or both, and IL-6 was measured in collected culture supernatants after a 24-h incubation. (D) HIGKs were stimulated for 24 h, or not, with P. gingivalis (MOI of 10:1) alone or with C3a (500 ng/ml), in the presence or absence of 10 mg/ml anti-TLR2 neutralizing Ab or isotype control (IC), which were added 2 h prior to stimulation. IL-6 release was assayed by ELISA. (E) HIGKs were pretreated with PD98059 (10 mM; MEK/ERK inhibitor), SP600125 (50mM; JNK inhibitor), SB202190 (20mM; p38 MAPK inhibitor), or SN50 (50mM, NF-kB inhibi- tor). After 1 h, Pam3Cys (1 mg/ml) was added in the cultures and C3aR expression (MFI) was determined by FACS after a 24-h incubation. (F) HIGKs were stimulated with Pam3Cys (1 mg/ml) for the indicated time lengths. Total protein was extracted and immunoblot analysis was performed with specific Abs against phosphorylated and total ERK1/2, JNK, and p38 MAPK as well as against GAPDH (loading control). (G) HIGKs were pretreated with Pam3Cys (1 mg/ml) for 4 h and then exposed to PD98059 (10 mM; MEK/ERK inhibitor), SP600125 (50mM; JNK inhibitor), SB202190 (20mM; p38 MAPK inhibitor), or SN50 (50mM, NF-kB inhibitor). After 1 h, C3a (500 ng/ml) was added in the cultures. Culture media were collected after 24 h and assayed for IL-6 by ELISA. Data are means ± SD (n 5 6 cultures per group). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 (A, D, E, and G, one-way ANOVA and a Tukey’s test; B and C, Dunnett’s multiple comparison tests).

Journal: Journal of immunology (Baltimore, Md. : 1950)

Article Title: Complement Is Required for Microbe-Driven Induction of Th17 and Periodontitis.

doi: 10.4049/jimmunol.2200338

Figure Lengend Snippet: FIGURE 5. C3a-induced IL-6 release in human gingival epithelial cells. (A) Human immortalized gingival keratinocytes (HIGKs) were stimulated, or not, with heat-killed P. gingivalis (MOI of 10:1), C3a, or C5a and combinations thereof (at the indicated concentrations). Culture media were collected after a 24-h incubation and assayed for IL-6 by ELISA. (B) HIGKs were stimulated for 24 h with heat-killed P. gingivalis (MOI of 10:1) or Pam3Cys lipopeptide (1 mg/ml) and C3aR expression was measured by FACS. Representative histogram (left) and bar graphs for mean fluorescence intensity (MFI) of C3aR expression (right). (C) HIGKs were stimulated, or not, with C3a (500 ng/ml), Pam3Cys (1 mg/ml), or both, and IL-6 was measured in collected culture supernatants after a 24-h incubation. (D) HIGKs were stimulated for 24 h, or not, with P. gingivalis (MOI of 10:1) alone or with C3a (500 ng/ml), in the presence or absence of 10 mg/ml anti-TLR2 neutralizing Ab or isotype control (IC), which were added 2 h prior to stimulation. IL-6 release was assayed by ELISA. (E) HIGKs were pretreated with PD98059 (10 mM; MEK/ERK inhibitor), SP600125 (50mM; JNK inhibitor), SB202190 (20mM; p38 MAPK inhibitor), or SN50 (50mM, NF-kB inhibi- tor). After 1 h, Pam3Cys (1 mg/ml) was added in the cultures and C3aR expression (MFI) was determined by FACS after a 24-h incubation. (F) HIGKs were stimulated with Pam3Cys (1 mg/ml) for the indicated time lengths. Total protein was extracted and immunoblot analysis was performed with specific Abs against phosphorylated and total ERK1/2, JNK, and p38 MAPK as well as against GAPDH (loading control). (G) HIGKs were pretreated with Pam3Cys (1 mg/ml) for 4 h and then exposed to PD98059 (10 mM; MEK/ERK inhibitor), SP600125 (50mM; JNK inhibitor), SB202190 (20mM; p38 MAPK inhibitor), or SN50 (50mM, NF-kB inhibitor). After 1 h, C3a (500 ng/ml) was added in the cultures. Culture media were collected after 24 h and assayed for IL-6 by ELISA. Data are means ± SD (n 5 6 cultures per group). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 (A, D, E, and G, one-way ANOVA and a Tukey’s test; B and C, Dunnett’s multiple comparison tests).

Article Snippet: The cells were seeded into 96-well plates at a density of 2 × 105 cells per well for 18 h and then challenged with heat-killed (65◦C, 1 h) P. gingivalis at a multiplicity of infection (MOI) of 10:1, in the presence or absence of different concentrations of recombinant human C3a or C5a (catalog no. 3677-C3-025 or 2037- C5-025/CF, R&D Systems) or the synthetic microbial lipopeptide Pam3Cys (catalog no. tlrl-pms, InvivoGen, San Diego, CA).

Techniques: Incubation, Enzyme-linked Immunosorbent Assay, Expressing, Fluorescence, Control, Western Blot, Comparison

The strong correlation between complement activation and CRC. ( A-D ) The associations between the mRNA levels of C3 (A), C5 (B), C5AR1 (C), and C5AR2 (D) and the overall survival of CRC patients (n=364). ( E, F ) The effect of C3 , C5 , C5ar1 or C5ar2 deficiency on AOM/DSS-induced colorectal tumorigenesis compared to WT control. Images of the colorectum, where CRC often developed at distal (rectum) sites (E), and quantitative analysis of tumor number and mass (F). The experiment was duplicated. Scale bar in (E), 1 cm. ( G ) Pathological analysis of control or tumor tissues, including H&E, Ki-67 and C3d staining. Scale bar, 100 µm for H&E and 50 µm for IHC. ( H ) C5a concentration in colon tissue homogenates (CTHs) measured by ELISA. n≥ 7 in each group of WT, C3 -KO, C5 -KO, C5ar1 -KO, or C5ar2 -KO mice. Data are represented as mean ± SEM; ns, not significant; * P <0.05; and *** P <0.001. NC, negative control.

Journal: Theranostics

Article Title: C5aR1 is a master regulator in Colorectal Tumorigenesis via Immune modulation

doi: 10.7150/thno.45058

Figure Lengend Snippet: The strong correlation between complement activation and CRC. ( A-D ) The associations between the mRNA levels of C3 (A), C5 (B), C5AR1 (C), and C5AR2 (D) and the overall survival of CRC patients (n=364). ( E, F ) The effect of C3 , C5 , C5ar1 or C5ar2 deficiency on AOM/DSS-induced colorectal tumorigenesis compared to WT control. Images of the colorectum, where CRC often developed at distal (rectum) sites (E), and quantitative analysis of tumor number and mass (F). The experiment was duplicated. Scale bar in (E), 1 cm. ( G ) Pathological analysis of control or tumor tissues, including H&E, Ki-67 and C3d staining. Scale bar, 100 µm for H&E and 50 µm for IHC. ( H ) C5a concentration in colon tissue homogenates (CTHs) measured by ELISA. n≥ 7 in each group of WT, C3 -KO, C5 -KO, C5ar1 -KO, or C5ar2 -KO mice. Data are represented as mean ± SEM; ns, not significant; * P <0.05; and *** P <0.001. NC, negative control.

Article Snippet: Then, mouse colon sections were incubated with an affinity purified pAb specific for mouse complement component C3d (1:80; R&D Systems, Minneapolis, MN), rabbit anti-Ki67 antibody (1 μg/ml; Abcam, Cambridge, MA) or rabbit anti-CD8 alpha antibody (1:1500; Abcam, Cambridge, MA) at 4°C overnight.

Techniques: Activation Assay, Control, Staining, Concentration Assay, Enzyme-linked Immunosorbent Assay, Negative Control

Inhibition of C3b and C4b deposition by r Em CRT and its functional binding regions measured by ELISA. ( A ) Pre-incubation of 100 μL C1qD (1:50) as source of natural MBL with different amounts of r Em CRT, r Em CRT-S, or r Em CRT-NP (0, 2, 4 μM) before adding into mannan-coated plates (50 μg/mL). After being washed, C1qD (1:150) was added as source of complement components to initiate lectin pathway of complement activation. Deposition of C3b ( a ) and C4b ( b ) was detected with anti-C3 or C4 monoclonal antibodies. ( B ) The similar ELISA procedure was performed using NHS as source of physiological MBL instead of C1qD serum to detect the generation of C3b (a) and C4b (b). Data are expressed as mean of OD 450 ± SDs of three independent experiments (* p < 0.005, ** p < 0.001, *** p < 0.0005, ns, no significant difference compared to plates without added r Em CRT).

Journal: Pathogens

Article Title: Echinococcus multilocularis Calreticulin Inhibits Lectin Pathway of Complement Activation by Directly Binding to Mannose-Binding Lectin

doi: 10.3390/pathogens14040354

Figure Lengend Snippet: Inhibition of C3b and C4b deposition by r Em CRT and its functional binding regions measured by ELISA. ( A ) Pre-incubation of 100 μL C1qD (1:50) as source of natural MBL with different amounts of r Em CRT, r Em CRT-S, or r Em CRT-NP (0, 2, 4 μM) before adding into mannan-coated plates (50 μg/mL). After being washed, C1qD (1:150) was added as source of complement components to initiate lectin pathway of complement activation. Deposition of C3b ( a ) and C4b ( b ) was detected with anti-C3 or C4 monoclonal antibodies. ( B ) The similar ELISA procedure was performed using NHS as source of physiological MBL instead of C1qD serum to detect the generation of C3b (a) and C4b (b). Data are expressed as mean of OD 450 ± SDs of three independent experiments (* p < 0.005, ** p < 0.001, *** p < 0.0005, ns, no significant difference compared to plates without added r Em CRT).

Article Snippet: After washing with 1 × TBST containing 5 mM CaCl 2 , the C1qD diluted at 1:150 in 1 × Veronal Buffer (VB, Lonza, Basel, Switzerland) containing 0.1% gelatin, 0.05% Tween-20 was added (100 μL) as supplement of other complement components (without C1q) into each well of the plates and incubated at 37 °C for 1 h. The lectin pathway-activated C3b/C4b deposition was detected with rabbit anti-C3b monoclonal antibody (1:1000, BOSTER Biological Technology, Wuhan, China) and goat anti-C4b polyclonal antibody (1:3000, Abcam, Cambridge, UK).

Techniques: Inhibition, Functional Assay, Binding Assay, Enzyme-linked Immunosorbent Assay, Incubation, Activation Assay, Bioprocessing